{"id":"https://openalex.org/W2980953181","doi":"https://doi.org/10.1182/blood.v112.11.3242.3242","title":"Dasatinib 100 Mg Once Daily (QD) Maintains Long-Term Efficacy and Minimizes the Occurrence of Pleural Effusion: An Analysis of 24-Month Data in Patients with Resistance, Suboptimal Response, or Intolerance to Imatinib (CA180-034).","display_name":"Dasatinib 100 Mg Once Daily (QD) Maintains Long-Term Efficacy and Minimizes the Occurrence of Pleural Effusion: An Analysis of 24-Month Data in Patients with Resistance, Suboptimal Response, or Intolerance to Imatinib (CA180-034).","publication_year":2008,"publication_date":"2008-11-16","ids":{"openalex":"https://openalex.org/W2980953181","doi":"https://doi.org/10.1182/blood.v112.11.3242.3242","mag":"2980953181"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v112.11.3242.3242","doi":"https://doi.org/10.1182/blood.v112.11.3242.3242","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.3242.3242","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050873337","display_name":"Kimmo Porkka","orcid":"https://orcid.org/0000-0003-4112-5902","observed_orcids":["https://orcid.org/0000-0003-4112-5902"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kimmo Porkka","raw_affiliation_strings":["Hematology Research Unit, Biomedicum Helsinki, Helsinki, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology Research Unit, Biomedicum Helsinki, Helsinki, Finland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107095127","display_name":"Hanna Jean Khoury","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I150468666","display_name":"Emory University","ror":"https://ror.org/03czfpz43","country_code":"US","type":"education","lineage":["https://openalex.org/I150468666"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. Jean Khoury","raw_affiliation_strings":["Emory University School of Medicine, Atlanta, GA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emory University School of Medicine, Atlanta, GA, USA","institution_ids":["https://openalex.org/I150468666"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110289135","display_name":"RONALD L. PAQUETTE","orcid":"https://orcid.org/0009-0009-8720-5562","observed_orcids":["https://orcid.org/0009-0009-8720-5562"]},"institutions":[{"id":"https://openalex.org/I2801272649","display_name":"Ronald Reagan UCLA Medical Center","ror":"https://ror.org/04k3jt835","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I2801272649"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald Paquette","raw_affiliation_strings":["Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I2801272649"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034600739","display_name":"Yousif Matloub","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Yousif Matloub","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, CT, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"David Liu","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055491299","display_name":"Ritwik Sinha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ritwik Sinha","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, CT, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015101485","display_name":"J\u00f6rge E. Cortes","orcid":"https://orcid.org/0000-0002-8636-1071","observed_orcids":["https://orcid.org/0000-0002-8636-1071"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jorge Cortes","raw_affiliation_strings":["Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5015101485","https://openalex.org/A5034600739","https://openalex.org/A5055491299"],"corresponding_institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I4210091812"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":1.2542,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.81874152,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"112","issue":"11","first_page":"3242","last_page":"3242"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9980000257492065},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.8889999985694885},{"id":"https://openalex.org/keywords/pleural-effusion","display_name":"pleural effusion","score":0.878000020980835},{"id":"https://openalex.org/keywords/bcr-abl-tyrosine-kinase-inhibitors","display_name":"BCR-ABL tyrosine kinase inhibitors","score":0.7379999756813049},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.8730000257492065},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.7739999890327454},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.5690000057220459},{"id":"https://openalex.org/keywords/long-term-efficacy","display_name":"long-term efficacy","score":0.7749999761581421},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5460000038146973},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.6909999847412109},{"id":"https://openalex.org/keywords/suboptimal-response","display_name":"suboptimal response","score":0.531000018119812}],"concepts":[{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.932758629322052},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8707453012466431},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6442873477935791},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.6387127041816711},{"id":"https://openalex.org/C2779634585","wikidata":"https://www.wikidata.org/wiki/Q1334541","display_name":"Pleural effusion","level":2,"score":0.6291984915733337},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.5709853172302246},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5397887825965881},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4151301383972168},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.34868496656417847},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.2946310341358185}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v112.11.3242.3242","doi":"https://doi.org/10.1182/blood.v112.11.3242.3242","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.3242.3242","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1987060661","https://openalex.org/W2564629313","https://openalex.org/W2564442020","https://openalex.org/W2588151101","https://openalex.org/W2886320425","https://openalex.org/W2281554724","https://openalex.org/W2010901133","https://openalex.org/W2567264821","https://openalex.org/W2139620048","https://openalex.org/W2563937343"],"abstract_inverted_index":{"Abstract":[0],"Dasatinib":[1],"(SPRYCEL\u00ae)":[2],"is":[3,9,33,494],"a":[4,49,151,431,453,482,519],"potent":[5,12,18],"BCR-ABL":[6,23],"inhibitor":[7],"that":[8,82,500],"325-fold":[10],"more":[11,17],"than":[13,19],"imatinib":[14],"and":[15,36,69,89,120,127,135,191,244,278,288,310,334,376,434,456,485],"16-fold":[16],"nilotinib":[20],"against":[21],"unmutated":[22],"in":[24,28,56,66,301,325,335,363,370,380,392,404,439,450,461,479,487,514],"vitro.":[25],"Pleural":[26,159],"effusion":[27,160,171,225,263,296,323,347,433,455,484,493,511,535,539],"patients":[29,58,124,144,184,202,217,303,312,327,337,365,372,382,394,403,419,515],"during":[30],"dasatinib":[31,83,130,187,501,529],"treatment":[32,442],"well":[34],"described":[35],"may":[37],"have":[38],"an":[39],"immune-mediated":[40],"mechanism,":[41],"although":[42],"this":[43],"remains":[44],"under":[45],"investigation.":[46],"CA180-034":[47],"was":[48,80,161,267,390,415,477],"4-arm":[50],"randomized,":[51],"phase":[52,68],"III,":[53],"dose-optimization":[54],"study":[55],"670":[57],"(662":[59],"treated":[60,128,145,185,203],"patients)":[61],"with":[62,97,129,134,141,186,204,275,430,452,481,516],"chronic":[63,67],"myeloid":[64],"leukemia":[65],"resistance,":[70],"suboptimal":[71],"response,":[72],"or":[73,106,211,517],"intolerance":[74],"to":[75,91,126,259,448,459],"prior":[76],"imatinib.":[77],"Previously,":[78],"it":[79],"demonstrated":[81],"100":[84,131,188,219,271,306,330,350,397,422,467,502,530],"mg":[85,103,108,132,189,206,209,213,220,272,283,286,290,307,331,351,398,423,468,503,531],"QD":[86,273,308,332,352,399,424,469,532],"maintained":[87],"efficacy":[88,527],"led":[90],"fewer":[92,114],"key":[93],"side":[94],"effects":[95],"compared":[96,140,274],"3":[98,316,341,357,393,407],"other":[99,147,315,340,356,406,441],"dosing":[100],"schedules":[101,149],"(140":[102],"QD,":[104,133,190,210,221,287],"50":[105,205,282],"70":[107,212,289,367],"twice":[109],"daily":[110,505],"[BID]),":[111],"including":[112],"significantly":[113],"pleural":[115,137,170,224,262,295,322,346,432,454,483,492,510,520,534,538],"effusions.":[116],"Here,":[117],"the":[118,142,305,314,329,339,349,355,396,405,421,440,466,471,507],"management":[119,344],"outcomes":[121],"of":[122,154,169,223,261,345,361,509,528],"165":[123,418],"randomized":[125],"without":[136,463,518],"effusion,":[138,521],"were":[139,179,254],"497":[143],"on":[146,157,304,313,328,338,348,395,420],"dose":[148,299],"after":[150],"minimum":[152],"follow-up":[153],"24":[155,177,231,558,579],"mos":[156,178,232,269,280],"CA180-034.":[158],"graded":[162],"using":[163],"standard":[164],"CTCAE":[165],"criteria.":[166],"Overall":[167,588],"rates":[168,222,444],"(all":[172],"grades)":[173],"at":[174,228,550,557,571,578],"12":[175,229,302],"vs":[176,181,193,196,199,230,237,242,248,354,366,373,383,401],"10%":[180],"14%":[182],"for":[183,201,270,281,294,321,417,428,436],"16%":[192],"23%,":[194],"21%":[195],"26%,":[197],"20%":[198],"25%":[200],"BID,":[207,214,284,291],"140":[208,285],"respectively.":[215,292],"In":[216,465,490],"receiving":[218],"by":[226],"grade":[227,234,239,245,251],"were:":[233],"1,":[235],"2%":[236,247],"1%;":[238],"2,":[240],"6%":[241],"10%;":[243],"3,":[246],"2%;":[249],"no":[250],"4":[252],"events":[253],"reported.":[255],"The":[256,409],"median":[257],"time":[258],"development":[260],"(of":[264],"any":[265],"grade)":[266],"10.3":[268],"9.5,":[276],"4.9,":[277],"4.5":[279],"Management":[293],"included":[297,359],"transient":[298],"interruptions":[300],"arm":[309,333,353,400],"71":[311],"arms":[317,358],"combined.":[318],"Dose":[319],"reductions":[320],"occurred":[324],"8":[326],"43":[336],"arms.":[342,408],"Medical":[343],"use":[360],"diuretics":[362,377],"13":[364],"patients,":[368,375],"corticosteroids":[369,379],"6":[371],"32":[374],"and/or":[378,387],"14":[381],"79":[384],"patients.":[385],"Diagnostic":[386],"therapeutic":[388],"thoracentesis":[389],"performed":[391],"9":[402],"overall":[410],"major":[411],"cytogenetic":[412],"response":[413],"rate":[414,476],"64%":[416],"arm,":[425,470],"comprising":[426],"70%":[427,546,560,581],"those":[429,437,451,462,480,488],"63%":[435,547],"without;":[438],"arms,":[443],"ranged":[445],"from":[446,457],"64":[447],"74%":[449],"59":[458],"61%":[460,567],"(Table).":[464],"24-mo":[472,497],"progression":[473],"free":[474],"survival":[475],"78%":[478,586],"80%":[486,587],"without.":[489],"conclusion,":[491],"medically":[495],"manageable;":[496],"data":[498],"show":[499],"once":[504],"minimizes":[506],"risk":[508],"and,":[512],"both":[513],"maintains":[522],"long-term":[523],"efficacy.":[524],"Table:":[525],"24-month":[526],"With":[533],"(n=23)":[536],"Without":[537],"(n=142)":[540],"Major":[541],"Cytogenetic":[542,563],"Response":[543,564],"(MCyR)":[544],"Rate":[545,566],"MCyR":[548,555],"Duration":[549,556,570,577],"18":[551,572],"mo":[552,559,573,580],"93%":[553,554,574],"90%":[561],"Complete":[562],"(CCyR)":[565],"49%":[568],"CCyR":[569,576],"95%":[575,582],"Progression":[583],"Free":[584],"Survival":[585,589],"89%":[590],"91%":[591]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-10-25T00:00:00"}